Merck breaks ground on $1B Delaware site to boost US supply chain

29.04.25 17:49 Uhr

Werte in diesem Artikel
Aktien

74,70 EUR 2,10 EUR 2,89%

123,05 EUR -0,50 EUR -0,40%

Indizes

PKT PKT

PKT PKT

1.926,9 PKT 13,8 PKT 0,72%

1.988,2 PKT 13,8 PKT 0,70%

22.425,8 PKT 154,2 PKT 0,69%

8.557,8 PKT 57,1 PKT 0,67%

1.774,4 PKT 12,8 PKT 0,72%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

200,5 PKT -0,5 PKT -0,25%

40.527,6 PKT 300,0 PKT 0,75%

540,3 PKT 1,7 PKT 0,31%

11.715,2 PKT 69,6 PKT 0,60%

22.517,0 PKT 197,0 PKT 0,88%

22.501,6 PKT 142,2 PKT 0,64%

16.300,3 PKT 42,9 PKT 0,26%

8.664,2 PKT 57,8 PKT 0,67%

17.117,7 PKT 124,0 PKT 0,73%

2.692,9 PKT 14,5 PKT 0,54%

5.560,8 PKT 32,1 PKT 0,58%

22.532,7 PKT 221,4 PKT 0,99%

Thousands of jobs could be on the horizon for American workers as drug manufacturer Merck takes steps to move manufacturing into the U.S., particularly in the form of a $1 billion state-of-the-art biologics center under construction in Wilmington, Delaware.In a FOX Business exclusive, company CEO Robert Davis told "Mornings with Maria" the effort will take time as Merck builds the capability, but the payoff could mean stable access to drugs in addition to high-paying jobs.Davis said Merck currently does contract manufacturing for the drug substance in the U.S. as well as outside the U.S. but the company is looking to have both substance and product in the U.S.MAN FROM INDIA ARRESTED IN TEXAS FOR ALLEGEDLY SELLING FAKE CANCER TREATMENT DRUGS TO PEOPLE IN US"For Ireland, what that means is not necessarily that we're going to close down operations, because we still have to serve the rest of the world, too," he explained on Tuesday."This is really an opportunity for us to [have the] U.S. [provide] for [the] U.S., [and] Europe [provide] for Europe, and have a much more risk-mitigated, resilient supply chain that has optionality that allows us to bring security. And as we think about national security, this is important security to the drug supply in the United States so that we can ensure that no matter what the situation is, U.S. patients get access to medicine."HOW TRUMP'S TARIFFS COULD IMPACT THE LABOR MARKETA news release from the company states Merck Wilmington Biotech will "comprise laboratory, manufacturing and warehouse capabilities to enable the launch and commercial production of next-generation biologics and therapies including potent antibody-drug conjugates (ADCs), reinforcing Merck’s focus on expanding and diversifying its pipeline."The site will also have production capabilities for the popular immunotherapy drug KEYTRUDA, which is used to treat cancer.CLICK HERE TO GET FOX BUSINESS ON THE GODavis said the location could initially provide 4,000 construction jobs and 500 full-time positions but expand to a workforce of 2,000 with 30,000 construction workers."It will be a meaningful opportunity both for tradesmen and for manufacturing to have good, high-quality paying jobs here in the United States," he added.Weiter zum vollständigen Artikel bei FOX Business

In eigener Sache

Übrigens: Merck und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Merck

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Merck

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: FOX Business

Nachrichten zu Merck KGaA

Wer­bung

Analysen zu Merck KGaA

DatumRatingAnalyst
29.04.2025Merck KaufenDZ BANK
28.04.2025Merck BuyGoldman Sachs Group Inc.
28.04.2025Merck Market-PerformBernstein Research
28.04.2025Merck OverweightJP Morgan Chase & Co.
25.04.2025Merck BuyUBS AG
DatumRatingAnalyst
29.04.2025Merck KaufenDZ BANK
28.04.2025Merck BuyGoldman Sachs Group Inc.
28.04.2025Merck OverweightJP Morgan Chase & Co.
25.04.2025Merck BuyUBS AG
25.04.2025Merck OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
28.04.2025Merck Market-PerformBernstein Research
10.04.2025Merck Market-PerformBernstein Research
06.03.2025Merck Market-PerformBernstein Research
07.01.2025Merck Market-PerformBernstein Research
18.10.2024Merck Market-PerformBernstein Research
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen